PATENT CLAIM ANALYSIS

Application Number: 15903649
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["424", "139100"]

Abstract:
The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Claim (Index 3):
The method according to  claim 1 , wherein the cancer is selected from the group consisting of colorectal cancer, pancreatic cancer, bladder cancer, leukemia, lymphoma, glioma, glioblastoma, melanoma, ovarian cancer, thyroid cancer, esophageal cancer, prostate cancer, and breast cancer.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.60274
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14936233', '16069144', '14947865', '14604415', '15744737']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7622396970011753
- 35 USC 102 Novelty (BERT): 0.6740292856191948
- Combined Prediction Score: 0.7534186558629774
- Mean Citation Score: 467.138764
- Max Citation Score: 696.6009
- Similarity Product: 640.2114572047591

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test